Nanobac Pharmaceuticals, Incorporated
NNBP · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | -92.2% | -65.7% | 83.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 17.6% | 64.5% | 65.1% | 72% |
| R&D Expenses | $1 | $2 | $1 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $2 | $1 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $3 | $8 |
| Operating Income | $5 | $5 | $3 | $8 |
| % Margin | 27,891.8% | 2,139% | 432% | 2,120.9% |
| Other Income/Exp. Net | -$2 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$7 | -$5 | -$4 | -$8 |
| Tax Expense | $2 | $0 | $1 | $0 |
| Net Income | -$7 | -$5 | -$4 | -$8 |
| % Margin | -37,319.7% | -2,209.5% | -561.4% | -2,197.4% |
| EPS | 0 | -0.025 | -0.02 | -0.052 |
| % Growth | 100% | -27.7% | 62.1% | – |
| EPS Diluted | 0 | -0.025 | -0.02 | -0.052 |
| Weighted Avg Shares Out | 0 | 199 | 189 | 153 |
| Weighted Avg Shares Out Dil | 0 | 199 | 189 | 153 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$6 | -$4 | -$3 | -$7 |
| % Margin | -33,646.8% | -1,880.6% | -434.9% | -1,920.8% |